Abstract
We investigated the correlation between FLT3 expression and IL10 gene promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1 and their clinical significance. FLT3 mRNA expression was measured by real-time quantitative PCR (qPCR) and immunohistochemical staining (IHC) on bone marrow (BM) leukemic cells. IL10 gene promoter polymorphisms including rs1800896 (G-1082A), rs1800871 (C-819T), and rs1800872 (C-592T) were genotyped by direct sequencing. Among 45 enrolled patients, 32 (71.1 %) exhibited FLT3 overexpression, whose FLT3 mRNA level was higher than normal cut-off value (0.02). The IHC results also consisted with FLT3 mRNA expression data achieved by qPCR. The FLT3 mRNA level was significantly different among 3 IHC staining groups (P < 0.0001); 0.031 ± 0.041, 0.106 ± 0.097 and 0.588 ± 0.573 in IHC negative, intermediate and positive group, respectively. Interestingly, the FLT3 expression level was correlated with the percentage of BM CD34 positive cells (R = 0.360, P = 0.016). The elevated FLT3 expression at initial BM were decreased after remission and maintained lower than the cut-off level. FLT3 expression was not dependent on IL10 gene promoter polymorphisms. FLT3 overexpression itself did not demonstrate significant effects on overall survival (OS). However, it is notable that IL10 rs1800896 GA genotype tended to have a lower estimated mean OS (20.1 months) compared to GG genotype (54.6 months), but the statistical significance was not derived because of limited number of patients in this study (P = 0.072). Further studies including more type of leukemia and patients may be helpful to understand the relations between cytokine genotype and FLT3 expression and their prognostic impact.
Similar content being viewed by others
References
Gilliland DG, Griffin JD (2002) The roles of FLT3 in hematopoiesis and leukemia. Blood 100(5):1532–1542. doi:10.1182/blood-2002-02-0492
Stirewalt DL, Radich JP (2003) The role of FLT3 in haematopoietic malignancies. Nat Rev Cancer 3(9):650–665. doi:10.1038/nrc1169
Kindler T, Lipka DB, Fischer T (2010) FLT3 as a therapeutic target in AML: still challenging after all these years. Blood 116(24):5089–5102. doi:10.1182/blood-2010-04-261867
Ozeki K, Kiyoi H, Hirose Y, Iwai M, Ninomiya M, Kodera Y, Miyawaki S, Kuriyama K, Shimazaki C, Akiyama H, Nishimura M, Motoji T, Shinagawa K, Takeshita A, Ueda R, Ohno R, Emi N, Naoe T (2004) Biologic and clinical significance of the FLT3 transcript level in acute myeloid leukemia. Blood 103(5):1901–1908. doi:10.1182/blood-2003-06-1845
Silva FP, Lind A, Brouwer-Mandema G, Valk PJ, Giphart-Gassler M (2007) Trisomy 13 correlates with RUNX1 mutation and increased FLT3 expression in AML-M0 patients. Haematologica 92(8):1123–1126
Dicker F, Haferlach C, Kern W, Haferlach T, Schnittger S (2007) Trisomy 13 is strongly associated with AML1/RUNX1 mutations and increased FLT3 expression in acute myeloid leukemia. Blood 110(4):1308–1316. doi:10.1182/blood-2007-02-072595
Baldwin BR, Li L, Tse KF, Small S, Collector M, Whartenby KA, Sharkis SJ, Racke F, Huso D, Small D (2007) Transgenic mice expressing Tel-FLT3, a constitutively activated form of FLT3, develop myeloproliferative disease. Leukemia 21(4):764–771. doi:10.1038/sj.leu.2404532
de Deus DM, de Souza PR, Muniz MT (2013) High FLT3 expression and IL10 (G1082A) polymorphism in poor overall survival in calla acute lymphoblastic leukemia. Mol Biol Rep 40(2):1609–1613. doi:10.1007/s11033-012-2209-4
Mangan JK, Speck NA (2011) RUNX1 mutations in clonal myeloid disorders: from conventional cytogenetics to next generation sequencing, a story 40 years in the making. Crit Rev Oncog 16(1–2):77–91
Zhang B, Ho YW, Huang Q, Maeda T, Lin A, Lee SU, Hair A, Holyoake TL, Huettner C, Bhatia R (2012) Altered microenvironmental regulation of leukemic and normal stem cells in chronic myelogenous leukemia. Cancer Cell 21(4):577–592. doi:10.1016/j.ccr.2012.02.018
Arber DA, Brunning RD, Le Beau MM, Falini B, Vardiman JW, Porwit A, Thiele J, Bloomfield CD (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds) WHO classification of tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 110–112
Kuchenbauer F, Kern W, Schoch C, Kohlmann A, Hiddemann W, Haferlach T, Schnittger S (2005) Detailed analysis of FLT3 expression levels in acute myeloid leukemia. Haematologica 90(12):1617–1625
Vora HH, Shukla SN, Brahambhatt BV, Mehta SH, Patel NA, Parikh SK, Shah KN, Shah PM (2010) Clinical relevance of FLT3 receptor protein expression in Indian patients with acute leukemia. Asia-Pac J Clin oncol 6(4):306–319. doi:10.1111/j.1743-7563.2010.01322.x
Grunwald MR, Levis MJ (2013) FLT3 inhibitors for acute myeloid leukemia: a review of their efficacy and mechanisms of resistance. Int J Hematol 97(6):683–694. doi:10.1007/s12185-013-1334-8
Eklund C, Jahan F, Pessi T, Lehtimaki T, Hurme M (2003) Interleukin 1B gene polymorphism is associated with baseline C-reactive protein levels in healthy individuals. Eur Cytokine Netw 14(3):168–171
Pociot F, Molvig J, Wogensen L, Worsaae H, Nerup J (1992) A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro. Eur J Clin Invest 22(6):396–402
Zheng L, Yin J, Wang L, Wang X, Shi Y, Shao A, Tang W, Ding G, Liu C, Chen S, Gu H (2013) Interleukin 1B rs16944 G > A polymorphism was associated with a decreased risk of esophageal cancer in a Chinese population. Clin Biochem 46(15):1469–1473. doi:10.1016/j.clinbiochem.2013.05.050
Zhang B, Li M, McDonald T, Holyoake TL, Moon RT, Campana D, Shultz L, Bhatia R (2013) Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-beta-catenin signaling. Blood 121(10):1824–1838. doi:10.1182/blood-2012-02-412890
Yao C, Du W, Chen H, Xiao S, Wang C, Fan Z (2013) Association of IL-10 gene promoter polymorphisms with acute myeloid leukemia in human, China. Asian Pac J Cancer Prev 14(4):2439–2442. doi:10.7314/APJCP.2013.14.4.2439
Cao HY, Zou P, Zhou H (2013) Genetic association of interleukin-10 promoter polymorphisms and susceptibility to diffuse large B-cell lymphoma: a meta-analysis. Gene 519(2):288–294. doi:10.1016/j.gene.2013.01.066
Saraiva M, O’Garra A (2010) The regulation of IL-10 production by immune cells. Nat Rev Immunol 10(3):170–181. doi:10.1038/nri2711
Brooks DG, Ha SJ, Elsaesser H, Sharpe AH, Freeman GJ, Oldstone MB (2008) IL-10 and PD-L1 operate through distinct pathways to suppress T-cell activity during persistent viral infection. Proc Natl Acad Sci USA 105(51):20428–20433. doi:10.1073/pnas.0811139106
Wang YC, Sung WW, Wang L, Cheng YW, Chen CY, Wu TC, Shieh SH, Lee H (2013) Different impact of IL10 haplotype on prognosis in lung squamous cell carcinoma and adenocarcinoma. Anticancer Res 33(6):2729–2735
Acknowledgments
This work was supported by a grant of the Korean Healthcare Technology R&D Project, Ministry for Health, Welfare & Family Affairs, Republic of Korea (SN: A092258) and a grant (10172KFDA993) from the Korea Food & Drug Administration in 2012 (to M Kim).
Conflict of interests
The authors have no conflict of interests.
Author information
Authors and Affiliations
Corresponding author
Electronic supplementary material
Below is the link to the electronic supplementary material.
Rights and permissions
About this article
Cite this article
Kim, M., Kim, J., Kim, J.R. et al. FLT3 expression and IL10 promoter polymorphism in acute myeloid leukemia with RUNX1-RUNX1T1 . Mol Biol Rep 42, 451–456 (2015). https://doi.org/10.1007/s11033-014-3786-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3786-1